AGAdriana van de Guchte

Adriana van de Guchte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adriana van de Guchte has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impaired neutralizing antibody responses against the BA1.1, BA.2, and BA.5 Omicron SARS-CoV-2 subvariants in hospitalized adults infected with pre-Omicron variants in Argentina

    by J. Sachithanandham, I. A. Sitaras, R. A. Albertini, R. H. Capra, J. Marquez, G. B. Sadino-Vallve, P. R. Gargantini, P. R. Cortes, N. E. Ponce, A. van de Guchte, et al.

    Infection with SARS-CoV-2 variants typically confers protective humoral immunity. Yet, the Omicron variant demonstrates a considerable capacity to evade immune responses in individuals previously infected with other SARS-CoV-2 strains. This has prompted investigation into Omicron’s potential resistance to neutralizing antibodies elicited by natural infection or vaccination. Importantly, the molecular mechanisms underlying this cross-protection have been investigated; however, they are not yet fully elucidated. In this study, we investigated the neutralization capacity of convalescent sera from COVID-19 patients in Córdoba City, Argentina, offering insights into immune responses against various SARS-CoV-2 variants. We analyzed samples from hospitalized patients infected with the Lambda and Gamma variants during the pandemic’s second wave from May to August 2021. These patients showed strong neutralization against Gamma, moderate activity against the B.1 and Delta variants, a weak response to Omicron BA.2, and extremely poor cross-neutralization against the Omicron BA.1.1 and BA.5 subvariants. Additionally, we examined convalescent sera from ambulatory patients during the fourth COVID-19 wave, from May to July 2022, when various Omicron variants predominated. Consistent with the hospitalized cohort, the highest neutralizing activity was observed against the Gamma variant, with moderate responses against B.1 and Delta, and low activity against Omicron subvariants. These findings highlight the critical need for region-specific studies of neutralizing responses to inform the development of future SARS-CoV-2 vaccine formulations. IMPORTANCE: Investigating the neutralizing capacity of sera obtained from COVID-19 patients infected with distinct viral variants—in this case, a comparison between pre-Omicron and Omicron strains—is essential for elucidating mechanisms of immune evasion, cross-protective immunity, and the efficacy of vaccines. Variations in neutralization profiles provide critical insights that inform the development of updated vaccines and booster immunization strategies, particularly given the pronounced immune escape characteristics exhibited by the Omicron variant. Furthermore, it is imperative to examine geographic heterogeneity, as regional differences in variant prevalence, vaccine types, and public health interventions contribute to diverse immune profiles. Conducting such investigations is critical for informing the development of tailored public health policies, facilitating the identification of immunological susceptibilities and resilience within distinct populations. This understanding is essential for improving preparedness in response to the emergence of new SARS-CoV-2 variants.

  • Top Cited Papers
    Open Access

    Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants

    by Ana S. Gonzalez-Reiche, Hala Alshammary, Sarah Schaefer, Gopi Patel, Jose Polanco, Juan Manuel Carreño, Angela A. Amoako, Aria Rooker, Christian Cognigni, Daniel Floda, et al.

    Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. Although intrahost evolution has been documented, direct evidence of subsequent transmission and continued stepwise adaptation is lacking. Here we describe sequential persistent SARS-CoV-2 infections in three individuals that led to the emergence, forward transmission, and continued evolution of a new Omicron sublineage, BA.1.23, over an eight-month period. The initially transmitted BA.1.23 variant encoded seven additional amino acid substitutions within the spike protein (E96D, R346T, L455W, K458M, A484V, H681R, A688V), and displayed substantial resistance to neutralization by sera from boosted and/or Omicron BA.1-infected study participants. Subsequent continued BA.1.23 replication resulted in additional substitutions in the spike protein (S254F, N448S, F456L, M458K, F981L, S982L) as well as in five other virus proteins. Our findings demonstrate not only that the Omicron BA.1 lineage can diverge further from its already exceptionally mutated genome but also that patients with persistent infections can transmit these viral variants. Thus, there is, an urgent need to implement strategies to prevent prolonged SARS-CoV-2 replication and to limit the spread of newly emerging, neutralization-resistant variants in vulnerable patients.


  • Open Access

    MRSA lineage USA300 isolated from bloodstream infections exhibit altered virulence regulation

    by Sophie Dyzenhaus, Mitchell J. Sullivan, Bremy Alburquerque, Daiane Boff, Adriana van de Guchte, Marilyn Chung, Yi Fulmer, Richard Copin, Juliana K. Ilmain, Anna O’kEefe, et al.


  • Open Access

    Outbreak of Highly Pathogenic Avian Influenza H5N1 in New England Seals

    by Wendy Puryear, Kaitlin Sawatzki, Nichola Hill, Alexa Foss, Jonathon J. Stone, Lynda Doughty, Dominique Walk, Katie Gilbert, Maureen Murray, Elena Cox, et al.

    The recent incursion of Highly Pathogenic Avian Influenza A (H5N1) virus into North America and subsequent dissemination of virus across the continent, has had significant adverse impacts on domestic poultry, and has led to widespread mortality in many wild bird species. Here we report the recent spillover of H5N1 into marine mammals in the northeastern United States, with associated mortality on a regional scale. This spillover is coincident with a second wave of H5N1 in sympatric wild birds also experiencing regional mortality events. Viral sequences derived from both seal and avian hosts reveal distinct viral genetic differences between the two waves of infection. Spillover into seals was closely related to virus from the second wave, and one of eight seal-derived sequences had the mammalian adaptation PB2 E627K. One-Sentence Summary An outbreak of H5N1 in New England seals is the first known population-scale mammalian mortality event associated with the emerging highly pathogenic avian influenza clade 2.3.4.4b.


  • RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City

    by Matthew M. Hernandez, Radhika Banu, Ana S. Gonzalez-Reiche, Brandon Gray, Paras Shrestha, Liyong Cao, Feng Chen, Huanzhi Shi, Ayman Hanna, Juan David Ramírez, et al.


  • Open Access

    Everybody nose: molecular and clinical characteristics of nasal colonization during active methicillin-resistant Staphylococcus aureus bloodstream infection

    by Erika Reategui Schwarz, Adriana van de Guchte, Amy C. Dupper, Ana Berbel Caban, Devika Nadkarni, Lindsey Fox, Alexandra Mills, Ajay Obla, Kieran I. Chacko, Irina Oussenko, et al.

    Background: Healthcare-associated infections pose a potentially fatal threat to patients worldwide and Staphylococcus aureus is one of the most common causes of healthcare-associated infections. S. aureus is a common commensal pathogen and a frequent cause of bacteremia, with studies demonstrating that nasal and blood isolates from single patients match more than 80% of the time. Here we report on a contemporary collection of colonizing isolates from those with methicillin-resistant S. aureus (MRSA) bloodstream infections to evaluate the diversity within hosts, and detail the clinical features associated with concomitant nasal colonization. Methods: Swabs of the bilateral anterior nares were obtained from patients diagnosed with MRSA bacteremia. A single colony culture from the blood and an average of 6 colonies from the nares were evaluated for MRSA growth. For the nares cultures, we typed multiple isolates for staphylococcal protein A (spa) and derived the clonal complexes. Demographic and clinical data were obtained retrospectively from the electronic medical record system and analysed using univariate and multivariable regression models. Results: Over an 11-month period, 68 patients were diagnosed with MRSA bloodstream infection, 53 were swabbed, and 37 (70%) were colonized with MRSA in the anterior nares. We performed molecular typing on 213 nasal colonies. Spa types and clonal complexes found in the blood were also detected in the nares in 95% of the cases. We also found that 11% of patients carried more than one clone of MRSA in the nares. Male sex and history of prior hospitalization within the past 90 days increased odds for MRSA colonization. Conclusion: The molecular epidemiological landscape of colonization in the setting of invasive disease is diverse and defining the interplay between colonization and invasive disease is critical to combating invasive MRSA disease.


  • Open Access

    Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

    by Juan Manuel Carreño, Hala Alshammary, Gagandeep Singh, Ariel Raskin, Fatima Amanat, Angela Amoako, Ana Silvia Gonzalez-Reiche, Adriana van de Guchte, PARIS study group, Komal Srivastava, et al.


  • Open Access

    SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia

    by Luz H. Patiño, Nathalia Ballesteros, Marina Muñoz, Sergio Castañeda, Carolina Hernández, Sergio Gomez, Carolina Florez, Angelica Rico, Liseth Pardo, Carlos E. Hernandez-Pereira, et al.


  • Open Access

    SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage

    by Alba Escalera, Ana S. Gonzalez-Reiche, Sadaf Aslam, Ignacio Mena, Rebecca L. Pearl, Manon Laporte, Andrea Fossati, Raveen Rathnasinghe, Hala Alshammary, Adriana van de Guchte, et al.

    For efficient cell entry and membrane fusion, SARS-CoV-2 spike (S) protein needs to be cleaved at two different sites, S1/S2 and S2’ by different cellular proteases such as furin and TMPRSS2. Polymorphisms in the S protein can affect cleavage, viral transmission, and pathogenesis. Here, we investigated the role of arising S polymorphisms in vitro and in vivo to understand the emergence of SARS-CoV-2 variants. First, we showed that the S:655Y is selected after in vivo replication in the mink model. This mutation is present in the Gamma Variant Of Concern (VOC) but it also occurred sporadically in early SARS-CoV-2 human isolates. To better understand the impact of this polymorphism, we analyzed the in vitro properties of a panel of SARS-CoV-2 isolates containing S:655Y in different lineage backgrounds. Results demonstrated that this mutation enhances viral replication and spike protein cleavage. Viral competition experiments using hamsters infected with WA1 and WA1-655Y isolates showed that the variant with 655Y became dominant in both direct infected and direct contact animals. Finally, we investigated the cleavage efficiency and fusogenic properties of the spike protein of selected VOCs containing different mutations in their spike proteins. Results showed that all VOCs have evolved to acquire an increased spike cleavage and fusogenic capacity despite having different sets of mutations in the S protein. Our study demonstrates that the S:655Y is an important adaptative mutation that increases viral cell entry, transmission, and host susceptibility. Moreover, SARS-COV-2 VOCs showed a convergent evolution that promotes the S protein processing.


  • Open Access

    Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin

    by Nathalia Ballesteros, Marina Muñoz, Luz Helena Patiño, Carolina Hernández, Felipe González-Casabianca, Iván Carroll, Mauricio Santos-Vega, Jaime Cascante, Andrés Angel, Alejandro Feged-Rivadeneira, et al.

    Background: The SARS-CoV-2 pandemic has forced health authorities across the world to take important decisions to curtail its spread. Genomic epidemiology has emerged as a valuable tool to understand introductions and spread of the virus in a specific geographic location.Methodology/Principal findings: Here, we report the sequences of 59 SARS-CoV-2 samples from inhabitants of the Colombian Amazonas department. The viral genomes were distributed in two robust clusters within the distinct GISAID clades GH and G. Spatial-temporal analyses revealed two independent introductions of SARS-CoV-2 in the region, one around April 1, 2020 associated with a local transmission, and one around April 2, 2020 associated with other South American genomes (Uruguay and Brazil). We also identified ten lineages circulating in the Amazonas department including the P.1 variant of concern (VOC).Conclusions/Significance: This study represents the first genomic epidemiology investigation of SARS-CoV-2 in one of the territories with the highest report of indigenous communities of the country. Such findings are essential to decipher viral transmission, inform on global spread and to direct implementation of infection prevention and control measures for these vulnerable populations, especially, due to the recent circulation of one of the variants of concern (P.1) associated with major transmissibility and possible reinfections.